1WHO/IPCS. Document No. 4. Part 1 : IPCS Cancer Mode of Action for Humans and Case-Studies. Part 2: IPCS Framework for Analysing the Relevance of a non Cancer Mode of Action for Humans. 2007.
2OECD. Guidance Document on Developing and Assessment Adverse Outcome Pathways, 2013.
4Zedan AH, Hansen TF, Svenningsen AF, et al. Oxaliplatin-induced neuropathy in coloreetal cancer: many questions with few answers [ J ]. Clin Colorectal Cancer, 2014, 13(2) : 73-80.
5Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study [J]. J Hepatol, 2013, 58 ( 1 ) : 81-88.
6Velasco It, Bruna J. Oxaliplatin Neurotoxicity [ J]. Curr Colorectal Cancer Rep, 2014, 10 (3) : 303-312.
7Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis [ J]. Gastric Cancer, 201 I, 14 ( 1 ) : 50-55.
8Stein A, Arnold D. Oxaliplatin: a review of approved uses [ J]. Expert Opin Pharmaeother, 2012, 13 ( 1 ) : 125-137.
9Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer [J]. Cancer, 2013, 119(2): 438-444.
10Sereno M, Guti6rrez-Guti6rrez G, G6mez-Raposo C, et al. Oxaliplatin indueed-neuropathy in digestive tumors [ J ]. Crit Rev Oncol Hematol, 2014, 89( 1 ) : 166-178.
